zuclopenthixol acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4075 85721-05-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zuclopenthixol acetate
  • clopixol acuphase
  • Molecular weight: 443
  • Formula: C24H27ClN2O2S
  • CLOGP: 5.03
  • LIPINSKI: 1
  • HAC: 4
  • HDO: 0
  • TPSA: 32.78
  • ALOGS: -5.90
  • ROTB: 7

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood prolactin abnormal 1049.40 171.91 163 2582 3103 90622599
Anosognosia 1037.11 171.91 163 2582 3359 90622343
Disturbance in social behaviour 1008.90 171.91 163 2582 4025 90621677
Sexual dysfunction 986.55 171.91 163 2582 4641 90621061
Metabolic disorder 914.67 171.91 163 2582 7307 90618395
Personality change 858.26 171.91 154 2591 7167 90618535
Dystonia 782.64 171.91 163 2582 16656 90609046
Dyskinesia 666.88 171.91 165 2580 36369 90589333
Sedation 645.61 171.91 170 2575 48001 90577701
Suicide attempt 539.76 171.91 163 2582 75236 90550466
Blood glucose increased 502.24 171.91 163 2582 95083 90530619
Insurance issue 191.51 171.91 48 2697 10910 90614792

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anosognosia 298.74 49.96 51 2166 993 42618125
Blood prolactin abnormal 298.20 49.96 51 2166 1004 42618114
Disturbance in social behaviour 264.60 49.96 50 2167 1753 42617365
Metabolic disorder 221.25 49.96 51 2166 4737 42614381
Sexual dysfunction 208.66 49.96 52 2165 6723 42612395
Dystonia 189.16 49.96 55 2162 12735 42606383
Dyskinesia 178.80 49.96 62 2155 25328 42593790
Personality change 161.64 49.96 41 2176 5678 42613440
Sedation 114.36 49.96 47 2170 30428 42588690
Suicide attempt 98.71 49.96 48 2169 46052 42573066
Blood glucose increased 95.93 49.96 55 2162 73644 42545474
Extrapyramidal disorder 67.27 49.96 27 2190 16385 42602733
Psychotic disorder 64.20 49.96 31 2186 29177 42589941
Neuroleptic malignant syndrome 63.49 49.96 28 2189 21444 42597674
Anxiolytic therapy 61.87 49.96 9 2208 57 42619061
Drug therapy enhancement 60.72 49.96 9 2208 66 42619052
Iatrogenic injury 60.49 49.96 13 2204 869 42618249
Antipsychotic drug level increased 55.54 49.96 17 2200 4649 42614469
Antipsychotic drug level decreased 51.27 49.96 12 2205 1181 42617937

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood prolactin abnormal 1121.18 63.87 184 4319 3651 110581145
Anosognosia 1110.07 63.87 184 4319 3890 110580906
Disturbance in social behaviour 1070.30 63.87 184 4319 4874 110579922
Sexual dysfunction 980.59 63.87 185 4318 8345 110576451
Metabolic disorder 935.94 63.87 184 4319 10326 110574470
Personality change 879.25 63.87 176 4327 10826 110573970
Dystonia 786.91 63.87 187 4316 25618 110559178
Dyskinesia 704.50 63.87 197 4306 51249 110533547
Sedation 636.87 63.87 195 4308 69488 110515308
Suicide attempt 545.77 63.87 191 4312 103203 110481593
Blood glucose increased 485.15 63.87 187 4316 132309 110452487
Insurance issue 202.64 63.87 53 4450 10559 110574237
Adverse drug reaction 185.81 63.87 89 4414 105470 110479326
Drug ineffective 126.31 63.87 222 4281 1520318 109064478
Personality change due to a general medical condition 112.49 63.87 18 4485 297 110584499
Condition aggravated 87.58 63.87 127 4376 734709 109850087
Extrapyramidal disorder 75.01 63.87 32 4471 28835 110555961
Anxiolytic therapy 64.06 63.87 9 4494 57 110584739
Drug therapy enhancement 64.06 63.87 9 4494 57 110584739

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
MeSH PA D014150 Antipsychotic Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018492 Dopamine Antagonists
CHEBI has role CHEBI:37890 α-adrenergic antagonist
CHEBI has role CHEBI:37955 H<small><sub>1</sub></small>-receptor antagonist
CHEBI has role CHEBI:48279 serotonergic antagonist
CHEBI has role CHEBI:48561 dopaminergic antagonist
CHEBI has role CHEBI:65190 first generation antipsychotic

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.47 Basic
pKa2 3.47 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
C0149491 UMLSCUI
C060342 MESH_SUPPLEMENTAL_RECORD_UI
349S2ZHF05 UNII
6436640 PUBCHEM_CID
58338 RXNORM
004070 NDDF
387566002 SNOMEDCT_US
395931006 SNOMEDCT_US
427940003 SNOMEDCT_US
C0009026 UMLSCUI
CHEBI:135722 CHEBI
DB13841 DRUGBANK_ID
12454 PUBCHEM_CID
1315 INN_ID
D003006 MESH_DESCRIPTOR_UI
349S2ZHF05 INXIGHT DRUGS

Pharmaceutical products:

None